Our study showed that copeptin, MR-proANP, and NT-proBNP led to modest but similar and consistent improvements in discrimination, calibration, and overall performance of both the ASTRAL and age/NIHSS models for the prediction of poor 1-year outcome in patients with mostly mild to moderate AIS. This evidence concerns the gene AVP and androgen insensitivity syndrome.